Seres Therapeutics (MCRB) Receivables - Other (2016 - 2025)

Seres Therapeutics (MCRB) posted Receivables - Other of $53000.0 for Q3 2025, down 81.0% sequentially from $279000.0 in Q2 2025.

Seres Therapeutics (MCRB) Receivables - Other (2016 - 2025) Analysis & Trends

Seres Therapeutics has reported Receivables - Other for 8 years, with the latest figure at $53000.0 in Q3 2025.

Quarterly Receivables - Other changed N/A year-over-year to $53000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $53000.0 (changed N/A YoY) and the FY2024 annual result came in at $2.7 million, down 69.07% from the prior year.
Receivables - Other retreated to $53000.0 in Q3 2025 per MCRB's latest filing, from $279000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $18.6 million in Q2 2024 and troughed at $53000.0 in Q3 2025.
A 3-year average of $7.1 million and a median of $7.4 million in 2024 frame the typical range for Receivables - Other.
The sharpest annual moves came in 2024 and 2025: Receivables - Other surged 146.08% in 2024, then plunged 98.5% in 2025.
Over 3 years, Receivables - Other stood at $8.7 million in 2023, then sank by 69.07% to $2.7 million in 2024, then slumped by 98.02% to $53000.0 in 2025.
According to Business Quant data, Receivables - Other over the past three periods registered $53000.0, $279000.0, and $1.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Seres Therapeutics	43.87 Mn	43.87 Mn	-

Download Data